Progress toward therapies: Projects in the pipeline

These active[1] disease-specific projects are in the later stages of moving toward clinical trials.

Find Out More:

Visit our Clinical Trials page for a complete list of all CIRM-funded clinical trials.
A complete list of all awards in a disease area, including those at an earlier stage of development at our Disease Fact Sheets.
The steps involved in developing a therapy, and the basic research that underlies all therapy development work on our Path to the Clinic page.

Descriptions of projects in development [pdf]

Active Therapy Development Projects

The Approved Funds represents the current award amount under agreement with the grantee which can be less the amount approved by the governing Board. For projects approved by the governing Board that have not yet been issued an award agreement, the Approved Funds will temporarily reflect the amount approved by the governing Board.

Disease areasort descendingTitleApproved fundsPhase
ALSStem Cells Secreting GDNF for the Treatment of ALS$63,487
ALSDevelopment of Novel Autophagy Inducers to Block the Progression of and Treat Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Diseases$2,278,080
AML or Solid TumorClinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors$6,505,568
Autism Spectrum Disorder (ASD)A drug-screening platform for autism spectrum disorders using human astrocytes$1,656,456
Bone fracturesGene Targeting to Endogenous Stem Cells for Segmental Bone Fracture Healing$5,180,674
CLLTherapeutic Eradication of Cancer Stem Cells$4,179,598
Conditioning regimen for allogeneic HSC transplantation for X-SCID A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants $19,068,382
Critical limb ischemia Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia$3,728,384
Diabetes: Type 1Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes$10,075,070
End stage heart failure with LVAD Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure$73,030
End stage heart failure with LVAD Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure$19,942,877
Heart dysfunction after MI/Chronic heart failureAllogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction$19,782,136
Hemophilia BDevelopment of a cell and gene based therapy for hemophilia$2,298,634
HIV/AIDSA Phase I, Open-Label Study to Assess the Safety, Feasibility and Engraftment of Zinc Finger Nucleases (ZFN) CCR5 Modified Autologous CD34+ Hematopoietic Stem/Progenitor Cells with Escalating Doses of Busulfan in HIV-1 (R5) Infected Subjects with Suboptim$5,583,438
HIV/AIDSStem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection$4,925,166
Huntington’s Disease MSC engineered to produce BDNF for the treatment of Huntington's disease$8,956,498
Limb Girdle Muscular Dystrophy Type 28Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B$1,876,253
MelanomaGenetic Re-programming of Stem Cells to Fight Cancer$19,875,776
Osteoporosis Treatment of osteoporosis with endogenous Mesenchymal stem cells$19,999,867
Prostate cancerClinical Development of an N-cadherin Antibody to Target Cancer Stem Cells$4,075,668
Retinitis PigmentosaRetinal progenitor cells for treatment of retinitis pigmentosa$17,144,825
Retinitis Pigmentosa, Age-related macular degeneration (dry form)Restoring vision by sheet transplants of retinal progenitors and retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs)$3,998,948
Sickle Cell DiseaseClinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease$13,145,465
Sickle Cell DiseaseBeta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells $1,652,076
Solid TumorA Phase I dose escalation and expansion clinical trial in patients with advanced solid tumors$6,924,317
Spinal Cord InjuryA Phase I/IIa Dose Escalation Safety Study of [REDACTED] in Patients with Cervical Sensorimotor Complete Spinal Cord Injury $14,323,318
StrokeProgramming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke$1,020,815
Urea Cycle DisordersGene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders$1,801,629
Ventricular arhythmias Improving Existing Drugs for Long QT Syndrome type 3 (LQT3) by hiPSC Disease-in-Dish Model$6,361,369


[1] The list does not include therapy-focused projects that have closed